Cognitive Impairment in Heart Failure
Author(s) -
Efthimios Dardiotis,
Grigorios Giamouzis,
Dimos Mastrogiannis,
Christina Vogiatzi,
John Skoularigis,
Filippos Triposkiadis,
Georgios M. Hadjigeorgiou
Publication year - 2012
Publication title -
cardiology research and practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.437
H-Index - 35
eISSN - 2090-8016
pISSN - 2090-0597
DOI - 10.1155/2012/595821
Subject(s) - medicine , dementia , cognition , psychomotor learning , heart failure , disease , intensive care medicine , quality of life (healthcare) , cerebral hypoxia , cognitive decline , hypoxia (environmental) , executive functions , affect (linguistics) , cerebral hypoperfusion , adverse effect , psychiatry , perfusion , psychology , ischemia , chemistry , nursing , organic chemistry , communication , oxygen
Cognitive impairment (CI) is increasingly recognized as a common adverse consequence of heart failure (HF). Although the exact mechanisms remain unclear, microembolism, chronic or intermittent cerebral hypoperfusion, and/or impaired cerebral vessel reactivity that lead to cerebral hypoxia and ischemic brain damage seem to underlie the development of CI in HF. Cognitive decline in HF is characterized by deficits in one or more cognition domains, including attention, memory, executive function, and psychomotor speed. These deficits may affect patients' decision-making capacity and interfere with their ability to comply with treatment requirements, recognize and self-manage disease worsening symptoms. CI may have fluctuations in severity over time, improve with effective HF treatment or progress to dementia. CI is independently associated with disability, mortality, and decreased quality of life of HF patients. It is essential therefore for health professionals in their routine evaluations of HF patients to become familiar with assessment of cognitive performance using standardized screening instruments. Future studies should focus on elucidating the mechanisms that underlie CI in HF and establishing preventive strategies and treatment approaches.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom